ISTH 2026 at a glance
ISTH 2026 brings emerging competitive dynamics into focus across von Willebrand disease (VWD) prophylaxis, hemophilia treatments, next-generation anticoagulants and AI-enabled diagnostics.
Key Themes at ISTH 2026: Emerging Competitive Developments
VWD Prophylaxis: Four-Week Subcutaneous Dosing Challenges Replacement-Based Care
VGA039/latarcibart will test whether four-week subcutaneous dosing can support a credible alternative to VWF/FVIII replacement-based prophylaxis.
Hemophilia Treatment Competition Shifts Toward Convenience and Differentiation
Mim8/denecimig, concizumab, NXT007, marstacimab, SR604, and Inno8 will compete on route, dosing interval, pediatric use, thrombin generation, and complex-care confidence.
Oral FVIII Mimicry: Inno8 Could Challenge Injection-Based Hemophilia Prophylaxis
Inno8 may raise the competitive threshold if early safety, pharmacokinetic (PK), and pharmacodynamic (PD) data support an oral alternative to injection-based prophylaxis.
Next-Generation Anticoagulants: Balancing Bleeding Risk and Clinical Efficacy
FXI/FXIa and FXII programs will face sharper scrutiny on whether lower bleeding risk can be paired with sufficient efficacy in defined clinical settings.
Competitor and Industry Signals at ISTH 2026
Novo Nordisk
Concizumab and FVIIIa mimetic sessions will emphasize precision dosing, functional hemostasis, device-enabled autonomy, and patient control.
CSL
HEMGENIX activity will focus on long-term outcomes, registries, patient-reported evidence, and post-approval implementation.
Novartis
Ianalumab plus eltrombopag will test whether second-line ITP strategy can move toward durability, sequencing logic, and broader disease modification.
Emerging Entrants Expand Competition Across Hemophilia and Thrombosis
SR604, SHR-2004, REGN9533, HMB-003, and REGN7508 will add new signals across hemophilia, VTE prevention, FXII inhibition, antifibrinolysis, and hemodialysis.
AI and Machine Learning at ISTH 2026: Clinical Diagnostics and Hemophilia Monitoring
AI-Enabled Diagnostics: Moving Toward Clinical Decision Support
AI activity will cluster around VTE identification, sepsis-induced DIC prediction, HIT peptide development, TTP diagnosis, and pulmonary embolism screening.
Hemophilia Monitoring: Predictive Models and Digital Twins
PK prediction and digital-twin arthropathy tools may support more personalized monitoring, but validation and workflow integration will remain decisive.
What We Are Watching Next in Hemophilia, VWD and Clinical AI Adoption
- Whether VGA039 produces consistent safety, PK/PD, and bleed-reduction evidence.
- Whether non-factor prophylaxis demonstrates meaningful differentiation beyond annualized bleeding rates.
- Whether Inno8 can challenge injection-based assumptions in hemophilia care.
- Whether AI tools progress from retrospective models toward clinically usable diagnostic and laboratory workflows.
Download the ISTH 2026 Preview Report
Download LucidQuest’s ISTH 2026 preview report for deeper analysis of emerging therapies, competitor positioning, and the key competitive developments shaping thrombosis and hemostasis.
📅 Build your schedule around the sessions that matter most.
📥 Download the ISTH 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
